证券代码：300558 证券简称：贝达药业 公告编号：2025-071 贝达药业股份有限公司 关于与晟斯生物达成战略合作暨签署《商业合作协议》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、贝达药业股份有限公司（以下简称"贝达药业"或"公司"）与江苏 晟斯生物制药有限公司（以下简称"江苏晟斯生物"）、杭州晟斯生物制药 有限公司（以下简称"杭州晟斯生物"，与"江苏晟斯生物"并称"晟斯生 物"）达成战略合作，签署《战略合作框架协议》，贝达药业将在研发、临 床、生产、注册及销售推广等环节给予晟斯生物支持，助推相关产品的研发、 产业化和商业化。《战略合作框架协议》为双方协商的框架性协议，就具体 合作事项，公司与晟斯生物将另行签署协议做出约定，该事项对公司2025年 度经营成果不构成重大影响。本协议自双方签字、盖章之日起生效。 2、公司全资子公司浙江贝达医药销售有限公司（以下简称"贝达医药销 售"）与杭州晟斯生物签署《杭州晟斯生物制药有限公司与浙江贝达医药销 售有限公司之商业合作协议》（以下简称"《商业合作协议》"），贝达医 药销售取得注射用培重 ...

Core Viewpoint - Beida Pharmaceutical has entered into a strategic cooperation with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to enhance its new drug innovation technology platform and expand its product pipeline [1] Group 1: Strategic Cooperation - The strategic cooperation aims to leverage the strengths of both parties to support mutual development [1] - A framework agreement has been signed to facilitate this collaboration [1] Group 2: Market Expansion - The partnership is focused on broadening the treatment areas and restructuring the blood product market [1] - This initiative is intended to better meet clinical needs and strengthen the company's product matrix [1] Group 3: Commercial Agreement - Beida Pharmaceutical has signed a commercial cooperation agreement with Hangzhou Shengsi Biopharmaceutical, granting exclusive distribution rights for the FRSW117 product in the Greater China region [1]

Core Viewpoint - The 2025 National Medical Insurance Directory negotiations are ongoing, focusing on pricing discussions for innovative drugs, particularly in the chronic disease medication sector [1] Group 1: Negotiation Details - The third day of the national negotiations began at approximately 1:40 PM, with participation from companies such as Novartis, Gensai, Roche, and Betta Pharmaceuticals [1] - The morning session emphasized negotiations on chronic disease medications, with Eli Lilly and Sinopharm bringing significant products to the discussions [1]

Core Viewpoint - Beida Pharmaceutical is a leading company in the domestic cancer drug research and development sector, focusing on innovative drug development with a strong technical team and a rich product line [1] Financial Performance - For Q3 2025, Beida Pharmaceutical reported revenue of 2.717 billion yuan, ranking 26th among 110 companies in the industry, with the industry leader, East China Pharmaceutical, generating 32.664 billion yuan [2] - The net profit for the same period was 303 million yuan, placing the company 28th in the industry, while the top performer, Hengrui Medicine, achieved a net profit of 5.76 billion yuan [2] Profitability and Debt Ratios - As of Q3 2025, Beida Pharmaceutical's debt-to-asset ratio was 38.97%, slightly up from 38.81% year-on-year, exceeding the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 80.34%, down from 83.81% year-on-year, but still above the industry average of 57.17% [3] Executive Compensation - The chairman, Ding Lieming, received a salary of 2.6508 million yuan in 2024, a decrease of 250,000 yuan compared to 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 7.99% to 29,500, while the average number of circulating A-shares held per account increased by 8.68% to 14,200 [5] Business Highlights - For the first three quarters of 2025, Beida Pharmaceutical achieved a revenue growth of 15.90% year-on-year, while the net profit decreased by 23.86% [6] - The company is seeing progress in its overseas expansion, with the eye drug EYP-1901 entering phase 3 clinical trials and sales of Ensartinib in the U.S. beginning to ramp up [6] - New products in the domestic market, such as recombinant human serum albumin and CDK4/6 inhibitor, are expected to contribute to revenue growth [6] Future Projections - Revenue projections for 2025, 2026, and 2027 are 3.569 billion yuan, 4.537 billion yuan, and 5.561 billion yuan, respectively, with net profits of 506 million yuan, 727 million yuan, and 921 million yuan [6] - The company is expected to maintain a "buy" rating with a target price of 77.71 yuan per share for 2026, based on a PE ratio of 45 times [6]

Core Insights - The company reported a revenue of 2.717 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 15.90%, while the net profit attributable to shareholders was 317 million yuan, a year-on-year decrease of 23.86% [1] - The overseas expansion is beginning to yield results, with the eye drug EYP-1901 entering Phase 3 clinical trials and expected to report data by mid-2026, while Ensartinib has started to see sales growth in the U.S. [1] - Multiple new products in the domestic market are expected to drive growth, including recombinant human serum albumin, CDK4/6 inhibitor Tazemetostat, and Trastuzumab, which have all begun to see sales [2] Financial Performance - For 2025, the company expects revenues of 3.569 billion yuan, 4.537 billion yuan in 2026, and 5.561 billion yuan in 2027, with net profits projected at 506 million yuan, 727 million yuan, and 921 million yuan respectively [3] - The corresponding EPS for these years is expected to be 1.21 yuan, 1.74 yuan, and 2.20 yuan, with PE ratios of 47.7x, 33.2x, and 26.2x respectively [3] Investment Outlook - Given the potential for product launches and a robust clinical development pipeline, the company is assigned a target price of 77.71 yuan per share based on a 2026 PE of 45x, maintaining a "Buy-A" investment rating [3]

Group 1 - The core viewpoint of the news is that 贝达药业 (Bida Pharmaceutical) has shown fluctuations in stock performance and financial metrics, with a notable increase in stock price on October 31, 2023, and mixed results in revenue and profit for the year [1][2]. Group 2 - As of October 31, 2023, 贝达药业's stock price increased by 2.27% to 56.38 CNY per share, with a total market capitalization of 23.721 billion CNY [1]. - The company reported a year-to-date stock price increase of 4.93%, but a decline of 0.98% over the last five trading days, 18.91% over the last 20 days, and 12.67% over the last 60 days [1]. - For the period from January to September 2025, 贝达药业 achieved a revenue of 2.717 billion CNY, representing a year-on-year growth of 15.90%, while the net profit attributable to shareholders decreased by 23.86% to 317 million CNY [2]. - The company has distributed a total of 669 million CNY in dividends since its A-share listing, with 184 million CNY distributed over the past three years [3]. - As of September 30, 2025, 贝达药业 had 29,500 shareholders, a decrease of 7.99% from the previous period, with an average of 14,198 circulating shares per shareholder, an increase of 8.68% [2].

Group 1 - The core point of the article is that Beida Pharmaceutical announced the release of a portion of its shares pledged by a shareholder, Ningbo Kaiming Investment Management Partnership [1] Group 2 - The number of shares released from pledge amounts to 3,270,000 shares [1]

证券代码：300558 证券简称：贝达药业 公告编号：2025-070 贝达药业股份有限公司 关于股东股份质押变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）今日接到股东宁波凯铭投资管理合伙企业 （有限合伙）（以下简称"凯铭投资"）函告，获悉凯铭投资持有本公司的部分股份发生质 押变动，现将具体情况公告如下： 一、股东股份质押基本情况 1、凯铭投资股份解除质押情况 | 股东 | 是否为控股股东或 | 本次解除质押 | 占其所持 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 第一大股东及其 | | | 总股本 | 起始日 | 解除日期 | 质权人 | | 名称 | 一致行动人 | 股份数量（股） | 股份比例 | 比例 | | | | | 凯铭投资 | 是 | 3,270,000 | 4.08% | 0.78% | 2024/6/20 | 2025/10/29 | 国元证券股份有限公司 | 2、股东股份累计质押情况 三、备查 ...

Group 1 - On October 29, 2025, BeiGene conducted a block trade of 257,400 shares, with a transaction value of 11.2278 million yuan, accounting for 1.33% of the total trading volume for the day [1] - The transaction price was 43.62 yuan, which represents a discount of 24.34% compared to the market closing price of 57.65 yuan [1] - The block trade involved multiple brokerage firms, including CITIC Securities and GF Securities, indicating active participation from institutional investors [2]

创新药概念股午后持续拉升，诺思格20cm涨停，普蕊斯、康芝药业涨超10%，泰格医药、康龙化成、 贝达药业涨幅居前。 ...